Neogen Co. (NASDAQ:NEOG – Get Free Report) Director James P. Tobin purchased 3,000 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was purchased at an average price of $16.86 per share, with a total value of $50,580.00. Following the acquisition, the director now directly owns 23,392 shares of the company’s stock, valued at approximately $394,389.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Neogen Stock Down 1.1 %
Shares of NASDAQ NEOG traded down $0.19 during mid-day trading on Friday, reaching $16.80. 1,036,043 shares of the company were exchanged, compared to its average volume of 2,120,224. Neogen Co. has a 1 year low of $11.46 and a 1 year high of $24.09. The firm has a 50-day moving average of $16.34 and a 200 day moving average of $15.24. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of 1,680.00 and a beta of 1.20. The company has a quick ratio of 2.66, a current ratio of 3.82 and a debt-to-equity ratio of 0.28.
Neogen (NASDAQ:NEOG – Get Free Report) last released its quarterly earnings results on Tuesday, July 30th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.02). The firm had revenue of $236.80 million for the quarter, compared to analysts’ expectations of $225.83 million. Neogen had a negative net margin of 1.02% and a positive return on equity of 3.09%. The business’s quarterly revenue was down 2.1% compared to the same quarter last year. During the same period in the previous year, the company posted $0.14 earnings per share. On average, research analysts expect that Neogen Co. will post 0.56 earnings per share for the current year.
Hedge Funds Weigh In On Neogen
Analysts Set New Price Targets
NEOG has been the subject of several research reports. StockNews.com upgraded Neogen to a “sell” rating in a report on Wednesday, July 10th. Piper Sandler upped their price objective on shares of Neogen from $17.00 to $17.50 and gave the stock a “neutral” rating in a research note on Tuesday.
View Our Latest Stock Analysis on NEOG
About Neogen
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.
Featured Stories
- Five stocks we like better than Neogen
- Industrial Products Stocks Investing
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Election Stocks: How Elections Affect the Stock Market
- MarketBeat Week in Review – 8/5 – 8/9
- What Makes a Stock a Good Dividend Stock?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.